Compacted PLGA Drug Formulations for Sustained Buprenorphine Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid use disorder (OUD) treatments, particularly buprenorphine formulations, face challenges such as diversion, non-adherence, high initial burst release, and complex manufacturing processes, which affect treatment efficacy and accessibility.
Innovation Solution
Development of biodegradable, compacted single-rod and microgranule formulations using PLGA that are free of interconnected pores, allowing for high drug loading, controlled release kinetics, and scalable manufacturing, minimizing initial burst release and extending therapy duration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If emulsion-based PLGA microparticle formulations are used, then drug delivery is achieved, but low drug loading and high initial burst release occur
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by using compacted rods instead of emulsion-based microparticles. This involves altering the manufacturing process parameters (compaction pressure, temperature) and formulation parameters (drug-to-polymer ratio, porosity) to achieve high drug loading (up to 90% w/w) while controlling the release profile and eliminating initial burst release through reduced interconnected porosity.
2Ease of manufacture
If traditional emulsion methods are used for microparticle preparation, then drug delivery systems are produced, but manufacturing complexity and cost increase
Solution Approach 1:
The patent extracts and eliminates the complex emulsion-based manufacturing process steps, replacing them with a simpler compaction process. This removes the need for organic solvents, emulsifiers, and multi-step processing, thereby reducing manufacturing complexity and enabling easier scalability while maintaining high drug loading capabilities.
3Ease of operation
If sublingual tablets and films are used, then buprenorphine treatment is provided, but medication diversion and non-adherence occur
Solution Approach 1:
The patent segments the treatment approach by providing both implantable rods for long-acting sustained release (improving adherence) and injectable microgranules for flexible administration (maintaining accessibility). This segmentation allows clinicians to choose the appropriate formulation based on patient needs, thereby maintaining treatment accessibility while improving adherence through extended-release options.
4Reliability
If extended-release depot injection is used, then diversion and non-adherence are reduced, but treatment duration and retention need further improvement
Solution Approach 1:
The patent uses composite materials by combining biodegradable PLGA polymer with high concentrations of buprenorphine (up to 90% w/w) in a compacted rod structure. This composite formulation provides extended-release depot injection capabilities while the high drug loading and controlled porosity enable prolonged treatment duration (3-6 months), thereby improving upon existing depot formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide sustained drug release for extended periods, improving treatment adherence and reducing manufacturing complexity, thus enhancing the effectiveness and accessibility of buprenorphine therapy for OUD.
Implementation Method 1
controlled release kinetics
Implementation Method 2
biodegradable poly(lactide-co-glycolide)
Data Source
AI summary
The present disclosure generally relates to formulations comprising a drug and biodegradable polymers that are compacted mechanically from a physical mixture to disrupt interconnected pores or open channels, resulting in substantially longer drug release times compared to non-compacted counterparts. The disclosure also includes methods of use and manufacture thereof.